Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg).

Whiteside TL, Mandapathil M, Schuler P.

Curr Med Chem. 2011;18(34):5217-23. Review.

2.

Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E₂ cooperation.

Mandapathil M, Whiteside TL.

Expert Opin Biol Ther. 2011 Sep;11(9):1203-14. doi: 10.1517/14712598.2011.581225. Epub 2011 Jun 26. Review.

3.

Disarming suppressor cells to improve immunotherapy.

Whiteside TL.

Cancer Immunol Immunother. 2012 Feb;61(2):283-8. doi: 10.1007/s00262-011-1171-7. Epub 2011 Dec 7. Review.

PMID:
22146892
4.

Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells.

Mandapathil M, Szczepanski MJ, Szajnik M, Ren J, Jackson EK, Johnson JT, Gorelik E, Lang S, Whiteside TL.

J Biol Chem. 2010 Sep 3;285(36):27571-80. doi: 10.1074/jbc.M110.127100. Epub 2010 Jun 17.

5.

Adenosine and prostaglandin e2 production by human inducible regulatory T cells in health and disease.

Whiteside TL, Jackson EK.

Front Immunol. 2013 Jul 25;4:212. doi: 10.3389/fimmu.2013.00212. eCollection 2013.

6.

Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?

Whiteside TL.

Cancer Immunol Immunother. 2014 Jan;63(1):67-72. doi: 10.1007/s00262-013-1490-y. Epub 2013 Nov 10. Review.

7.

Regulatory T-cells and cAMP suppress effector T-cells independently of PKA-CREM/ICER: a potential role for Epac.

Vang AG, Housley W, Dong H, Basole C, Ben-Sasson SZ, Kream BE, Epstein PM, Clark RB, Brocke S.

Biochem J. 2013 Dec 15;456(3):463-73. doi: 10.1042/BJ20130064.

PMID:
24007532
8.

Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.

Bastid J, Regairaz A, Bonnefoy N, Déjou C, Giustiniani J, Laheurte C, Cochaud S, Laprevotte E, Funck-Brentano E, Hemon P, Gros L, Bec N, Larroque C, Alberici G, Bensussan A, Eliaou JF.

Cancer Immunol Res. 2015 Mar;3(3):254-65. doi: 10.1158/2326-6066.CIR-14-0018. Epub 2014 Nov 17.

9.

Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells.

Romio M, Reinbeck B, Bongardt S, Hüls S, Burghoff S, Schrader J.

Am J Physiol Cell Physiol. 2011 Aug;301(2):C530-9. doi: 10.1152/ajpcell.00385.2010. Epub 2011 May 18.

PMID:
21593451
10.

What are regulatory T cells (Treg) regulating in cancer and why?

Whiteside TL.

Semin Cancer Biol. 2012 Aug;22(4):327-34. doi: 10.1016/j.semcancer.2012.03.004. Epub 2012 Mar 28. Review.

11.

Multifaceted effects of synthetic TLR2 ligand and Legionella pneumophilia on Treg-mediated suppression of T cell activation.

van Maren WW, Nierkens S, Toonen LW, Bolscher JM, Sutmuller RP, Adema GJ.

BMC Immunol. 2011 Mar 24;12:23. doi: 10.1186/1471-2172-12-23.

12.

Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression.

Strauss L, Bergmann C, Szczepanski MJ, Lang S, Kirkwood JM, Whiteside TL.

J Immunol. 2008 Mar 1;180(5):2967-80.

13.

Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer.

Mandapathil M, Szczepanski MJ, Szajnik M, Ren J, Lenzner DE, Jackson EK, Gorelik E, Lang S, Johnson JT, Whiteside TL.

Clin Cancer Res. 2009 Oct 15;15(20):6348-57. doi: 10.1158/1078-0432.CCR-09-1143. Epub 2009 Oct 13.

14.

Influence of serum and soluble CD25 (sCD25) on regulatory and effector T-cell function in hepatocellular carcinoma.

Cabrera R, Ararat M, Eksioglu EA, Cao M, Xu Y, Wasserfall C, Atkinson MA, Liu C, Nelson DR.

Scand J Immunol. 2010 Oct;72(4):293-301. doi: 10.1111/j.1365-3083.2010.02427.x.

15.
16.

Ncf1 (p47phox) is essential for direct regulatory T cell mediated suppression of CD4+ effector T cells.

Efimova O, Szankasi P, Kelley TW.

PLoS One. 2011 Jan 6;6(1):e16013. doi: 10.1371/journal.pone.0016013.

17.

Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs.

Whiteside TL, Mandapathil M, Szczepanski M, Szajnik M.

Bull Cancer. 2011 Feb;98(2):E25-31. doi: 10.1684/bdc.2010.1294. Review.

18.

Molecular Mechanisms for cAMP-Mediated Immunoregulation in T cells - Role of Anchored Protein Kinase A Signaling Units.

Wehbi VL, Taskén K.

Front Immunol. 2016 Jun 8;7:222. doi: 10.3389/fimmu.2016.00222. eCollection 2016. Review.

19.

Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.

Nagayama Y, Hase W, Motoyoshi Y, Saitoh O, Sogawa R, Nakao K.

Oncol Rep. 2007 May;17(5):1269-73.

PMID:
17390075
20.

PTPROt maintains T cell immunity in the microenvironment of hepatocellular carcinoma.

Hou J, Deng L, Zhuo H, Lin Z, Chen Y, Jiang R, Chen D, Zhang X, Huang X, Sun B.

J Mol Cell Biol. 2015 Aug;7(4):338-50. doi: 10.1093/jmcb/mjv047. Epub 2015 Jun 27.

PMID:
26117839

Supplemental Content

Support Center